Clinical Operations & Strategy

Considerations to help tailor new tools as part of a custom clinical trial strategy.

Melissa Easy, VP and GM, clinical technologies at IQVIA speaks about what should be top of mind for clinops professionals in 2023 at the SCOPE 2023 conference in Orlando, FL.

Hope Meely, chief clinical officer at Slope, provides a brief summary of her SCOPE presentation revolving around biospecimen collection.

Hope Meely, chief clinical officer at Slope, discusses the feedback she received following her SCOPE presentation around biospecimen collection.

Researchers face various challenges that cause their clinical trials to fail to meet enrollment timelines, among other issues.

Webinar Date/Time: Thursday, March 30th, 2023 at 10am EDT|7am PDT|3pm BST|4pm CEST

Laboratory services organization focuses on easing patient and site burden with improved collection device.

Webinar Date/Time: Thu, Mar 9, 2023 11:00 AM EST

21st Century Cures Act prompts FDA to harmonize regulations.

Already existing enrollment challenges emphasized by single patient sites.

Webinar Date/Time: Tue, Feb 21, 2023 11:00 AM EST

Webinar Date/Time: Tue, Mar 14, 2023 11:00 AM EDT

Tim Bray, chief sourcing and training officer at Virb discusses how CROs and sponsors can mitigate risks by onboarding CRAs with less experience.

Webinar Date/Time: Thu, Jan 26, 2023 11:00 AM EST

Study by Tufts CSDD uncovers potential reasons behind CRA shortages, turnover, experience requirements, and more.

Economic challenges combined with increased responsibility for clinical trial workers has shifted talent recruitment.

Webinar Date/Time: Tuesday, December 13, 2022 at 10am ET | 3pm GMT | 4pm CET

Tufts CSDD study addresses barriers in recruitment.

Ukraine invasion tests the resiliency and quick action of CROs and sponsors.

Experts gauge threat level for global trials amid staffing and funding issues.

Phesi and Tufts CSDD share results from research on operating practices that can be improved.

The benefits of working with an institutional biosafety committee in CGT research.

Insights from Bayer’s study review process showcases importance of incorporating feedback from a wider audience of stakeholders.

A more crowded space is presenting new challenges for stakeholders that must be addressed to improve efficiency.

Increased outreach is necessary to combat poor recruitment and large focus on patients near study centers.